ACUVUE® Abiliti™ 1-Day AAO Showcase: 3-year data, vision and wearability outcomes
Sponsored by
Johnson & Johnson MedTech shared new findings on ACUVUE® Abiliti™ 1-Day at the American Academy of Optometry 2026 meeting; here, we summarise all the research.
The American Academy of Optometry hosted its 104th annual meeting in Anaheim, USA from September 30 to October 3, 2026. The meeting brought together 7,648 eye care practitioners, researchers and students to explore the latest developments in vision science and clinical practice.
Among the research presented, Johnson & Johnson MedTech shared new findings on ACUVUE® Abiliti™ 1-Day, a soft contact lens with a novel RingBoost™ technology developed for paediatric myopia management. The presentations explored three-year myopia control efficacy, objective and subjective visual performance, fitting and wear characteristics, and children's experiences of lens handling and comfort. This article summarises the research.
3-year efficacy and safety data on the ACUVUE® Abiliti™ 1-Day
Xu Cheng presenting the 3-year data for the ACUVUE® Abiliti™ 1-Day at American Academy of Optometry 2026.
A prospective, multinational, double-blind randomised controlled trial (RCT) evaluated ACUVUE® Abiliti™ 1-Day against single-vision (SV) daily disposable contact lenses in 191 myopic children aged 7–12 years. Participants had baseline refractive errors ranging from −0.75 D to −4.50 D, with astigmatism of up to 1.00 D. Conducted across eight clinical sites in North America and two in Asia, the study included 97 children in the ACUVUE® Abiliti™ 1-Day group and 94 in the SV control group, with 149 completing the three-year follow-up.
The study's two co-primary efficacy endpoints were axial elongation and change in spherical equivalent cycloplegic auto refraction (SECAR) over three years. Visual performance, subjective vision and ocular safety were also assessed. Key findings were as follows.
- Significant reductions in axial elongation and myopia progression
At three years, children wearing ACUVUE® Abiliti™ 1-Day demonstrated 58% slower axial elongation and 73% less myopia progression than controls.
| Outcome (3 years) | ACUVUE® Abiliti™ 1-Day | Single-vision control | Treatment effect |
| Axial elongation | 0.20 mm | 0.51 mm | 58% reduction (0.31 mm) |
| Myopia progression | −0.25 D | −0.97 D | 73% reduction (0.72 D) |
2. A substantial proportion of treated eyes demonstrated minimal or no progression
28% of treated eyes demonstrated no axial elongation over three years, compared with only 2% of control eyes. More than 50% of treated eyes experienced no clinically meaningful myopia progression (≤0.25 D) over three years, compared with 13% of control eyes. These findings suggest that a substantial proportion of children experienced strong treatment responses, with some demonstrating axial length stability.
3. Safety outcomes over three years
Over 36 months, no serious contact lens-related ocular adverse events or cases of microbial keratitis were reported. Approximately 16% of participants experienced contact lens-related adverse events, most of which were mild and non-serious.
Visual performance of the ACUVUE® Abiliti™ 1-Day
One consideration when designing myopia control contact lenses is the potential trade-off between treatment optics and visual quality. Introducing higher levels of myopic defocus may influence retinal image quality, making objective visual acuity and subjective visual experience important outcomes to evaluate.
Monocular and binocular high-contrast visual acuity, alongside subjective visual experiences assessed using the paediatric Contact Lens User Experience (pCLUE) questionnaire were evaluated in children (n=191) wearing either the ACUVUE® Abiliti™ 1-Day or SV soft contact lenses over 3 years.
- Monocular and binocular visual acuity remained consistently 20/20 (6/6) or better across all study visits.
- Visual acuity was approximately 2–3 letters (i.e. 0.04 to 0.06 logMAR) lower with ACUVUE® Abiliti™ 1-Day than with SV contact lenses.1
- More than 90% of participants provided positive responses to several subjective vision questions (questions covered distance vision, near vision, crispness, peripheral vision, all-day clarity, and other visual disturbances such as haloes), with differences between treatment and control groups generally below 10%.2
- Negative responses were less frequent, typically occurring in fewer than 5% of participants.
Despite incorporating relatively high treatment powers, ACUVUE® Abiliti™ 1-Day maintained good visual performance over three years.
Clinical usability, fit & wear time with ACUVUE® Abiliti™ 1-Day
Co-author Alex Nixon (left) and Paul Gifford (right, Myopia Profile co-founder and not a co-author!) pictured with the abstract poster at the American Academy of Optometry 2026 poster session.
Beyond myopia control efficacy, practical considerations such as lens fitting, handling and wear time are important in paediatric myopia management with soft contact lenses. Using data from the 3-year RCT, fitting and wearing time of the ACUVUE® Abiliti™ 1-Day was compared with SV contact lenses.
An acceptable lens fit was observed in 100% of eyes in both groups at initial fitting and throughout the 3-year follow-up. Among Abiliti™ 1-Day wearers, 95.3% of eyes accepted the initial lens power without modification. Prescription updates were required in 7.0–17.9% of eyes at follow-up visits between six and 36 months; this rate was lower than that observed with the SV contact lenses which required updates in 8.4% to 26.9% of eyes across the same visits.
Most children in both groups were successfully dispensed their lenses after a single insertion and removal training visit (Abiliti™ 1-Day: 86.5%; SV: 91.5%). For children wearing Abiliti™ 1-Day, average daily wear time increased from 11.4 hours at one month to 13.2 hours at 36 months, with an average wear frequency of 6.5 days per week at 36 months.
Fitting and managing Abiliti™ 1-Day over 3 years requires no extra chair time or frequent prescription adjustments compared to conventional soft contact lenses, making patient follow-ups straightforward and predictable.
How do children perceive contact lens comfort and handling?
Co-author Alex Nixon pictured with the abstract poster at the American Academy of Optometry 2026 poster session.
A single-masked crossover study evaluated a subgroup of 38 children aged 7–12 years who wore a “run in” single vision soft contact lens (etalficon A hydrogel) for one week, before being fitted with three daily disposable lens designs which were worn for two weeks each: Abiliti™ 1-Day (senofilcon A silicone hydrogel), MiSight 1 day (omafilcon A hydrogel) and an enhanced-vision prototype (senofilcon A silicone hydrogel). Comfort and handling were assessed using the Pediatric Comfort and Handling Questionnaire (PCHQ).
Children reported differences in lens application and comfort between designs, with variations apparent from initial fitting and persisting after two weeks.
- Lens handling: At initial fitting, the average proportion of most favourable responses was 62.8% for Abiliti™ 1-Day, 32.2% for MiSight 1 day and 61.2% for the enhanced-vision prototype. After two weeks, these increased to 67.1%, 43.8% and 67.6%, respectively.
- Lens comfort: At initial fitting, the corresponding proportions for comfort-related questions were 53.1%, 35.5% and 66.3%, respectively.
Lens material and geometry may have contributed to these differences, however the findings should be interpreted cautiously given the small sample size and descriptive analysis without formal statistical comparisons.
Children's perceptions of contact lens handling and comfort can differ between lens materials and designs, even at initial fitting. Clinicians can consider these factors alongside clinical fitting assessments when selecting myopia control contact lenses, as they may influence the child's wearing experience and acceptance of treatment.
Final thoughts
The research presented at AAO 2026 contributes to the growing evidence base for soft contact lenses in myopia management, providing further insights into the efficacy, visual performance, safety and practical aspects of ACUVUE® Abiliti™ 1-Day. These findings highlight the importance of a comprehensive approach to myopia management, where treatment selection considers not only the ability to slow myopia progression, but also the individual child's visual needs, comfort and wearing experience of soft contact lenses.
Meet the Authors:
About Jeanne Saw
Jeanne is a clinical optometrist based in Sydney, Australia. She has worked as a research assistant with leading vision scientists, and has a keen interest in myopia control and professional education.
As Manager, Professional Affairs and Partnerships, Jeanne works closely with Dr Kate Gifford in developing content and strategy across Myopia Profile's platforms, and in working with industry partners. Jeanne also writes for the CLINICAL domain of MyopiaProfile.com, and the My Kids Vision website, our public awareness platform.
This content is brought to you thanks to an educational grant from
References
Cheng X. Three-year efficacy of a novel soft contact lens for myopia control in children. Paper presentation in Myopia Control Interventions session. American Academy of Optometry 2026 Meeting: September 30–October 3, 2026; Anaheim, CA.
Nti AN, Nixon AD, Xu J, Mayer C, Cheng X. Three-year objective and subjective vision outcomes with a non-coaxial multi-zone myopia control soft contact lens in children. Poster presentation. American Academy of Optometry 2026 Meeting: September 30–October 3, 2026; Anaheim, CA.
Nixon A, Nti A, Hester-Hotte E, Xu J, Mayer C, Cheng X. Beyond Efficacy: Fit and Wear Performance of a Novel Myopia Control Lens in Children. Poster presentation. American Academy of Optometry 2026 Meeting: September 30–October 3, 2026; Anaheim, CA.
Nixon A, Nti A, Hester-Hotte E, Xu J, Mayer C, Cheng X. Children 7–12 Years Perceive Differences in MCSCL Handling and Comfort. Poster presentation. American Academy of Optometry 2026 Meeting: September 30–October 3, 2026; Anaheim, CA.
Enormous thanks to our visionary sponsors
Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.